Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Previous work indicates that 2 months androgen pre-treatment may equip preantral follicles
with more FSH receptors and increase the cohort of follicles surviving to the recruitable
antral stage. In this regard it may result in an increase in the oocyte yield and the
reproductive outcome in women with poor ovarian response. These findings provide a strong
rationale for a definitive large RCT. The TTRANSPORT study will include 400 women with poor
ovarian response randomized to receive pre-treatment with transdermal testosterone gel or
placebo in order to provide conclusive evidence regarding the superiority or not of
transdermal testosterone pre-treatment for the management of poor ovarian responders
fulfilling the Bologna criteria.